Management of ACS in Patients Already on a DOAC
Continue the DOAC at the therapeutic dose for stroke prevention and add antiplatelet therapy, with the specific regimen depending on whether the patient undergoes PCI or is managed medically. 1
Initial Anticoagulation Strategy During PCI
Administer additional parenteral anticoagulation during PCI regardless of the timing of the last DOAC dose. 1 This is critical because DOACs alone do not provide adequate procedural anticoagulation during coronary intervention.
Unfractionated heparin should be given as a bolus during the procedure to maintain adequate anticoagulation for the intervention itself. 1, 2
Post-PCI Antithrombotic Regimen
The default strategy after PCI is dual antithrombotic therapy (DAT) consisting of the DOAC plus a single antiplatelet agent, preferably clopidogrel, after a brief period of triple therapy. 1
Triple Antithrombotic Therapy (TAT) Duration
Periprocedural DAPT (aspirin plus clopidogrel) should be given for up to 1 week after the acute event. 1
After uncomplicated PCI, aspirin should be discontinued within 1 week, followed by continuation of the DOAC and clopidogrel. 1, 3
Dual Antithrombotic Therapy (DAT) Duration
Continue DOAC plus clopidogrel for up to 6 months in patients not at high ischemic risk. 1, 3
Extend DAT to 12 months in patients at high ischemic risk (complex PCI, multivessel disease, left main disease, or other high-risk anatomical/procedural characteristics). 1
After 12 months, discontinue all antiplatelet therapy and continue DOAC monotherapy. 1
DOAC Dose Adjustments for Bleeding Risk
In patients at high bleeding risk (HAS-BLED ≥3), consider dose-reduced DOACs during the period of concomitant antiplatelet therapy:
Dabigatran 110 mg twice daily (instead of 150 mg) should be considered to mitigate bleeding risk. 1
Rivaroxaban 15 mg once daily (instead of 20 mg) should be considered when bleeding concerns outweigh thrombotic risk. 1
Apixaban and edoxaban dosing should follow standard stroke prevention recommendations based on renal function, age, and weight. 1
Medically Managed ACS (No PCI)
For patients managed without revascularization, continue the DOAC plus a single antiplatelet agent (preferably clopidogrel) for up to 1 year. 1
- After 1 year, transition to DOAC monotherapy. 1
Critical Medications to Avoid
Never use ticagrelor or prasugrel as part of triple antithrombotic therapy with a DOAC. 1, 3 These potent P2Y12 inhibitors dramatically increase bleeding risk when combined with oral anticoagulation and should only be considered as part of DAT (without aspirin) in highly selected patients with very high ischemic risk. 1
Bleeding Prophylaxis
A proton pump inhibitor is mandatory for all patients receiving combined antithrombotic therapy (DOAC plus antiplatelet agents) to reduce gastrointestinal bleeding risk. 3
Common Pitfalls to Avoid
Do not discontinue the DOAC in favor of antiplatelet therapy alone, as this exposes the patient to stroke risk if the DOAC indication (atrial fibrillation, VTE, mechanical valve) remains present. 1, 4
Do not continue triple therapy beyond 1 week in uncomplicated cases, as prolonged TAT substantially increases major bleeding without proportional ischemic benefit. 1
Do not use fixed-dose heparin during PCI; weight-based dosing is essential to avoid under-anticoagulation. 2
Do not empirically reduce the DOAC dose unless the patient meets high bleeding risk criteria, as underdosing increases stroke and thrombotic risk. 1